# FibroBiologics, Inc.: financial statements, quarterly

FBLG · Nasdaq · CIK 1958777 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/fblg.md) · [Financials](/companies/fblg/financials.md) · [Filings](/companies/fblg/filings.md) · [Insiders](/companies/fblg/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/fblg/financials.md?period=annual).

## Income statement

| Line item | Unit | period not labelled (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Research and development | $k | [571](/filings/0001493152-24-044736.md) | [773 d](/filings/0001641172-25-001691.md) | [960](/filings/0001641172-25-010252.md) | [975](/filings/0000950170-25-100917.md) | [1,213](/filings/0001193125-25-260774.md) | [1,356 d](/filings/0001193125-26-066965.md) | [1,780](/filings/0001193125-26-197858.md) | [2,041](/filings/0001193125-26-328454.md) | [2,789](/filings/0001193125-25-260774.md) | [797 d](/filings/0001193125-26-066965.md) | [2,953](/filings/0001193125-26-197858.md) | [1,658](/filings/0001193125-26-328454.md) |
| Operating income | $k | [(2,052)](/filings/0001493152-24-044736.md) | [(2,480) d](/filings/0001641172-25-001691.md) | [(3,450)](/filings/0001641172-25-010252.md) | [(3,224)](/filings/0000950170-25-100917.md) | [(3,352)](/filings/0001193125-25-260774.md) | [(3,712) d](/filings/0001193125-26-066965.md) | [(4,531)](/filings/0001193125-26-197858.md) | [(4,490)](/filings/0001193125-26-328454.md) | [(5,038)](/filings/0001193125-25-260774.md) | [(2,590) d](/filings/0001193125-26-066965.md) | [(5,068)](/filings/0001193125-26-197858.md) | [(4,033)](/filings/0001193125-26-328454.md) |
| Interest expense | $k | not reported | not reported | [4.0](/filings/0001493152-24-019225.md) | [5.0](/filings/0001493152-24-030603.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $k | not reported | not reported | not reported | not reported | [0.0 d](/filings/0001193125-25-260774.md) | [0.0 d](/filings/0001193125-26-066965.md) | [0.0](/filings/0001193125-26-197858.md) | [0.0 d](/filings/0001193125-26-328454.md) | [0.0 d](/filings/0001193125-25-260774.md) | [0.0 d](/filings/0001193125-26-066965.md) | [0.0](/filings/0001193125-26-197858.md) | [0.0 d](/filings/0001193125-26-328454.md) |
| Net income | $k | [(2,193)](/filings/0001493152-24-044736.md) | [(9,717) d](/filings/0001641172-25-001691.md) | [(8,460)](/filings/0001193125-25-260774.md) | [898](/filings/0001193125-25-260774.md) | [(500)](/filings/0001193125-25-260774.md) | [(3,099) d](/filings/0001193125-26-066965.md) | [(4,966)](/filings/0001193125-26-328454.md) | [(4,658)](/filings/0001193125-26-328454.md) | [(5,778)](/filings/0001193125-25-260774.md) | [(3,244) d](/filings/0001193125-26-066965.md) | [(5,000)](/filings/0001193125-26-328454.md) | [(4,117)](/filings/0001193125-26-328454.md) |
| Diluted EPS | $ per share | [(0.08)](/filings/0001493152-24-044736.md) | not reported | [(0.27)](/filings/0001641172-25-010252.md) | [0.03](/filings/0000950170-25-100917.md) | [(0.01)](/filings/0001193125-25-260774.md) | not reported | [(2.71)](/filings/0001193125-26-197858.md) | [(2.41)](/filings/0001193125-26-328454.md) | [(0.13)](/filings/0001193125-25-260774.md) | not reported | [(1.33)](/filings/0001193125-26-197858.md) | [(0.66)](/filings/0001193125-26-328454.md) |
| Basic EPS | $ per share | [(0.08)](/filings/0001493152-24-044736.md) | not reported | [(0.27)](/filings/0001641172-25-010252.md) | [0.03](/filings/0000950170-25-100917.md) | [(0.01)](/filings/0001193125-25-260774.md) | not reported | [(2.71)](/filings/0001193125-26-197858.md) | [(2.41)](/filings/0001193125-26-328454.md) | [(0.13)](/filings/0001193125-25-260774.md) | not reported | [(1.33)](/filings/0001193125-26-197858.md) | [(0.66)](/filings/0001193125-26-328454.md) |

- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | period not labelled (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | not reported | [9.2](/filings/0001641172-25-001691.md) | [8.2](/filings/0001493152-24-019225.md) | [6.0](/filings/0001493152-24-030603.md) | [7.8](/filings/0001493152-24-044736.md) | [14.0](/filings/0001193125-26-066965.md) | [8.7](/filings/0001641172-25-010252.md) | [8.8](/filings/0000950170-25-100917.md) | [4.9](/filings/0001193125-25-260774.md) | [4.9](/filings/0001193125-26-328454.md) | [1.5](/filings/0001193125-26-197858.md) | [3.5](/filings/0001193125-26-328454.md) |
| Current assets | $m | not reported | [9.2](/filings/0001641172-25-001691.md) | [8.9](/filings/0001493152-24-019225.md) | [6.5](/filings/0001493152-24-030603.md) | [8.2](/filings/0001493152-24-044736.md) | [14.2](/filings/0001193125-26-066965.md) | [9.3](/filings/0001641172-25-010252.md) | [10.2](/filings/0000950170-25-100917.md) | [5.2](/filings/0001193125-25-260774.md) | [6.3](/filings/0001193125-26-328454.md) | [2.9](/filings/0001193125-26-197858.md) | [5.9](/filings/0001193125-26-328454.md) |
| Total assets | $m | not reported | [11.8](/filings/0001641172-25-001691.md) | [11.4](/filings/0001493152-24-019225.md) | [8.9](/filings/0001493152-24-030603.md) | [10.5](/filings/0001493152-24-044736.md) | [16.4](/filings/0001193125-26-066965.md) | [11.4](/filings/0001641172-25-010252.md) | [13.9](/filings/0000950170-25-100917.md) | [8.7](/filings/0001193125-25-260774.md) | [9.6](/filings/0001193125-26-328454.md) | [5.9](/filings/0001193125-26-197858.md) | [7.9](/filings/0001193125-26-328454.md) |
| Current liabilities | $m | not reported | [9.2](/filings/0001641172-25-001691.md) | [14.0](/filings/0001493152-24-019225.md) | [10.1](/filings/0001493152-24-030603.md) | [6.7](/filings/0001493152-24-044736.md) | [12.7](/filings/0001193125-26-066965.md) | [8.2](/filings/0001641172-25-010252.md) | [11.0](/filings/0000950170-25-100917.md) | [6.7](/filings/0001193125-25-260774.md) | [1.8](/filings/0001193125-26-328454.md) | [1.8](/filings/0001193125-26-197858.md) | [2.2](/filings/0001193125-26-328454.md) |
| Total liabilities | $m | not reported | [10.6](/filings/0001641172-25-001691.md) | [15.3](/filings/0001493152-24-019225.md) | [11.3](/filings/0001493152-24-030603.md) | [7.7](/filings/0001493152-24-044736.md) | [13.7](/filings/0001193125-26-066965.md) | [9.1](/filings/0001641172-25-010252.md) | [13.0](/filings/0000950170-25-100917.md) | [8.6](/filings/0001193125-25-260774.md) | [3.5](/filings/0001193125-26-328454.md) | [3.3](/filings/0001193125-26-197858.md) | [3.3](/filings/0001193125-26-328454.md) |
| Short-term borrowings | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [10.5](/filings/0001493152-24-044736.md) | [1.3](/filings/0001193125-26-066965.md) | [(3.9)](/filings/0001193125-25-260774.md) | [(2.4)](/filings/0001193125-25-260774.md) | [2.7](/filings/0001193125-25-260774.md) | [2.7](/filings/0001193125-26-328454.md) | [2.4](/filings/0001193125-26-328454.md) | [0.9](/filings/0001193125-26-328454.md) | [0.1](/filings/0001193125-25-260774.md) | [6.2](/filings/0001193125-26-328454.md) | [2.6](/filings/0001193125-26-328454.md) | [4.6](/filings/0001193125-26-328454.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Short-term borrowings: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | period not labelled (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(1,139) d](/filings/0001493152-24-044736.md) | [(1,601) d](/filings/0001641172-25-001691.md) | [(4,275)](/filings/0001641172-25-010252.md) | [(1,947) d](/filings/0000950170-25-100917.md) | [(2,606) d](/filings/0001193125-25-260774.md) | [(3,073) d](/filings/0001193125-26-066965.md) | [(5,275)](/filings/0001193125-26-197858.md) | [(3,984) d](/filings/0001193125-26-328454.md) | [(3,972) d](/filings/0001193125-25-260774.md) | [(3,163) d](/filings/0001193125-26-066965.md) | [(4,364)](/filings/0001193125-26-197858.md) | [(3,291) d](/filings/0001193125-26-328454.md) |
| Capital expenditure | $k | [413 d](/filings/0001493152-24-044736.md) | [2.0 d](/filings/0001641172-25-001691.md) | [8.0](/filings/0001641172-25-010252.md) | [66.0 d](/filings/0000950170-25-100917.md) | [11.0 d](/filings/0001193125-25-260774.md) | [99.0 d](/filings/0001193125-26-066965.md) | [43.0](/filings/0001193125-26-197858.md) | [213 d](/filings/0001193125-26-328454.md) | [6.0 d](/filings/0001193125-25-260774.md) | [0.0 d](/filings/0001193125-26-066965.md) | [0.0](/filings/0001193125-26-197858.md) | [0.0 d](/filings/0001193125-26-328454.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | period not labelled (2023-03-31) | period not labelled (2023-06-30) | period not labelled (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [28.2](/filings/0001493152-24-019225.md) | [28.2](/filings/0001493152-24-030603.md) | [28.2](/filings/0001493152-24-044736.md) | [31.1](/filings/0001641172-25-010252.md) | [32.7](/filings/0000950170-25-100917.md) | [33.5](/filings/0001193125-25-260774.md) | [1.8](/filings/0001193125-26-197858.md) | [1.9](/filings/0001193125-26-328454.md) | [43.1](/filings/0001193125-25-260774.md) | [3.8](/filings/0001193125-26-197858.md) | [6.3](/filings/0001193125-26-328454.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 6,658,193 at 2026-07-31, from the cover of the [10-Q filed 2026-07-31](/filings/0001193125-26-328454.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:50 ET. No prices; not investment advice.